Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Merge entities : Eli lilly and company save search
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Published: 2022-02-11 (Crawled : 21:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
covid-19 treatment covid authorization merge emergency use authorization
180 Degree Capital Corp. Portfolio Company, D-Wave Systems, Inc., Announces Intent to Become a Public Company Through a Merger With DPCM Capital, Inc. and Provides an Update on Legacy Private Portfolio Monetization Efforts
Published: 2022-02-08 (Crawled : 14:30) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
TURN | $3.98 -0.25% 4.8K
|
Finance
|
| O: 0.97%
H: 8.67%
C: 5.98%
ces system one merge
Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12
Published: 2021-12-05 (Crawled : 00:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: 0.0%
fda authorization bioscience merge emergency use authorization
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Published: 2021-12-03 (Crawled : 22:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K
|
|
| O: 3.41%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
covid therapy authorized antibody merge
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
Published: 2021-12-03 (Crawled : 20:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
covid therapy authorized antibody merge
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
covid expansion merge authorized emergency use authorization
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.14%
H: 0.49%
C: -0.26%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid merge authorized emergency use authorization
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K
|
|
| O: -0.11%
H: 5.8%
C: 5.38%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid fda merge authorized emergency use authorization
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
Published: 2021-07-29 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.64%
H: 0.14%
C: -1.41%
covid baricitinib fda oxygen merge
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
Global Active Pharmaceutical Ingredient (API) Market Report 2021-2025: Opportunities in Advancements in API Manufacturing, Growth in the CMOs, & Emergence of Biosimilars Market
Published: 2021-05-10 (Crawled : 12:15) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 6.39%
H: 3.3%
C: 0.4%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.63%
H: 1.13%
C: 0.08%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.05%
H: 0.37%
C: -0.02%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.76%
H: 0.27%
C: -0.28%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 0.22%
C: -0.72%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.31%
H: 1.01%
C: 0.09%
ALB | $112.15 0.31% -0.13% 2M
|
Process Industries
|
| O: 0.41%
H: 1.07%
C: -2.39%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.54%
H: 0.17%
C: -0.32%
cmo growth merge biosimilar
Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements
Published: 2021-05-04 (Crawled : 11:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
covid baricitinib therapy india merge license
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Published: 2021-04-16 (Crawled : 11:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.79%
H: 1.56%
C: 1.0%
covid treatment merge authorized emergency use authorization
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
Published: 2021-04-05 (Crawled : 13:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.19%
H: 0.17%
C: -0.38%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 1.3%
C: 1.21%
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 2.0%
H: 1.52%
C: -3.42%
renal biotech iot merge program
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
Published: 2021-03-26 (Crawled : 13:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.28%
H: 2.0%
C: 1.95%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.52%
H: 1.01%
C: 0.68%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.27%
H: 1.56%
C: -3.45%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.31%
H: 1.33%
C: 1.22%
covid treatment fda biotech technology iot merge submission authorized emergency use authorization
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 08:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda merge authorized covid-19 emergency use authorization
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 07:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K
|
|
| O: 12.77%
H: 0.06%
C: -11.34%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda antibody merge authorized covid-19 emergency use authorization
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
Published: 2021-02-10 (Crawled : 01:15) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda merge authorized emergency use authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.